Cite

HARVARD Citation

    Tomoto, K. et al. (n.d.). ACT-11 CLINICAL BENEFIT OF ADD-ON BEVACIZUMAB FOR NEWLY DIAGNOSED GLIOBLASTOMA IN ELDERLY PATIENTS WITH UNRESECTABLE AND POOR PERFORMANCE STATUS. Neuro-oncology advances. p. iii8. [Online]. 
  
Back to record